| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 117.95 Cr | 3.0% | 52.9% |
| Total Income | 119.44 Cr | 2.2% | 53.6% |
| Expenditure | 111.11 Cr | 5.2% | 52.8% |
| PBT | 8.32 Cr | 25.5% | 65.8% |
| Net Profit | 7.22 Cr | 36.8% | 63.4% |
| OPM | 14.02% | 1.84pp | 1.37pp |
| NPM | 6.04% | 3.73pp | 0.36pp |
| EPS | 6.27 | 36.9% | 44.8% |
Strong growth masking margin compression; recovery dependent on utilization ramp
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Delivered 52.9% YoY growth (beat 25% prior minimum). Margin targets implicitly lowered from 18% EBITDA to ~15-16% in statements; PAT 9-10% guidance faces credibility test if Q2 doesn't show uptick.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (52.9% YoY) and healthy order book (₹225 Cr) support near-term momentum. However, Q1 margins compressed to 6% PAT vs. 9-10% year-end guidance, and EBITDA slipped to 15.3% vs. prior 18% target. Management's narrative—that appraisals, labor agreement, UAE logistics, and input costs caused temporary margin hit—is plausible but unproven; margin recovery depends entirely on capacity utilization improving in Q3-Q4. Key risk: UAE concentration (69% of Q1 revenue) amid geopolitical uncertainty.
₹117.9 Cr
Revenue · +52.9% YoY₹7.2 Cr
Reported PAT · +63.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Consolidated EBITDA increased 44% YoY to ₹18 Cr
OVERSTATED₹18 Cr EBITDA = 15.3% margin; prior target was 18% EBITDA margin in FY26
PAT growing 63% YoY to ₹7.22 Cr
MET₹7.22 Cr delivered; but PAT down 36.8% QoQ, signal of deterioration within year
9-10% PAT margin guidance for FY27
OVERSTATEDQ1 delivered 6.0% PAT margin; implies +3-4 pp improvement required in Q2-Q4
EBITDA margin improvement ~1% over upcoming quarters
OVERSTATEDCurrent 15.3% vs. prior 18% target = 2.7 pp shortfall; ~1% improvement falls well short
Strong order inflow ₹50 Cr India, AED72 Mn UAE
METOrder book confirmed at these levels; execution timeline 6-9 months provides revenue visibility
Earnings quality
What changed since the last call
Margin target downgrade (implicit)
DowngradePrior guidance ₹400 Cr+ revenue with 16-16.5% EBITDA for FY26; now 9-10% PAT for FY27 with 15.3% actual EBITDA. Moved from 18% EBITDA aspiration to 1% improvement language (lower bar).
Revenue guidance widened
UpgradePrior 25% minimum now 25-40% range with 'potential upside'; Q1 beat at 52.9% validates upside case but makes minimum look conservative.
Capacity expansion accelerated
UpgradeUAE third line AED15 Mn (24 lakh sq meter total capacity); Taloja and Erode ramp targets by Q4 (75%, 25-30% utilization). India capacity +₹75 Cr potential revenue via acquisitions.
Geographic mix rebalancing
NeutralUAE contribution was 75% last year; target 60-40 this year, 50-50 next year. Diversification into Africa, Europe, India expansion ongoing.
The Q&A
Analysts (Raj Saraf, Nishitha, Shanki Bansal) pressed hard on margin compression. Q1 at lowest margin in 5-6 quarters sparked questions on sustainability. Management held firm—blamed appraisals, labor agreement, logistics, input costs as one-offs; cited utilization ramp as recovery driver. Tone confident but candid on constraints (capacity scaling, debtor cycles, management bandwidth). Q&A revealed some guidance inconsistency (25% vs. 50% mentioned in prior TV interview), which Gada addressed as 'minimum 25%, potential 40%'. Overall: tough but not hostile pushback; management answered directly.
Margin guidance FY27 — Gaurav Shukla, Finvestors
AnsweredEBITDA improved ~1%; PAT nearly 9% expected this year. (Rambhia clarified.)
Revenue vs. margin progression — Preet Shah, Blue Star Capital
PartialQ3 and Q4 will see margin impact; capacity utilization improvement drives fixed cost distribution. (Gada: expect 9-10% PAT.)
Capacity utilization by plant — Nishitha, Sapphire Capital
AnsweredSilvassa 77%→85-90%, Taloja 55%→75%, Erode 15%→25-30%, UAE 71%→85% by Q4. Third line 15-20% (starts Q3). (Rambhia detailed.)
New verticals (railway, fire-rated, bulletproof) — Rohit, Vijit Global
AnsweredRailway <1% now, increasing. Fire product starts Q3. Targeting 10% total from these verticals next year. (Gada.)
Drivers of margin pressure in Q1 — Raj Saraf, Finvestors
AnsweredPerformance appraisals/increment (~₹1 Cr impact), Taloja labor union agreement, UAE logistics disruption in June, input cost +1% (diesel, energy). Q2 onwards improvement. (Gada, Rambhia.)
Order book execution timeline — Nishitha, Sapphire Capital
AnsweredIndia ₹50+ Cr, UAE AED70 Mn (~₹175 Cr). Execution 6-9 months. Regular small orders also coming in. (Rambhia.)
Working capital, tax, debt levels — Nitin, Individual
AnsweredIndia WC ~98 days, UAE ~85 days. Tax: India no tax (carry-forward losses ~4-5 yrs remaining), UAE 9% corporate tax. Debt India ₹52 Cr total (₹38 Cr term loan, ₹14 Cr WC debt). (Rambhia.)
UAE capacity constraints and release timing — Shanki Bansal, Individual
AnsweredTailor-made product; customer must release size based on site readiness, architect approvals. Takes time. July crossed AED11.87 Mn—tracking upward. (Rambhia.)
Long-term growth and competitive positioning — Shanki Bansal, Individual
AnsweredMaintain 25-40% annual growth range. Asahi focused on automotive (90%), Saint-Gobain on float. Sejal is only listed pure-play architectural glass. Regional SME dominance in India, no multinational threat. (Gada.)
UAE capex funding — Shanki Bansal, Individual
AnsweredInternal accruals + AED7 Mn bank debt proposed (50-50 debt-equity split). Total AED15 Mn. (Rambhia.)
Geographic concentration risk — Nitin, Individual
AnsweredYes, derisking UAE: target 60-40 (this year), 50-50 (next year). Railway <1% ramping, automotive replacement market being explored. Industrial products also. (Gada.)
Capacity ceiling and future revenue potential — Nitin, Individual
AnsweredCurrent capacity ~₹600 Cr potential; post-third line, Taloja, Erode acquisition ₹75 Cr additional (~₹675 Cr total). (Gada affirmed.)
Competitive moat and margin by vertical — Mithun, Individual
AnsweredArchitecture gives highest margins. Management focused on architectural as core. (Gada.)
Guidance
FY27 revenue growth 25% minimum, 40% potential upside
MediumBased on FY26 ₹396 Cr base (implied guidance 25% = ₹495 Cr, 40% = ₹554 Cr). Q1 at 52.9% growth suggests FY27 will easily beat minimum. Management cautious on upper end citing geopolitical volatility, management capacity scaling, debtor cycles.
EBITDA margin +1% improvement over upcoming quarters from Q2 onwards
MediumQ1 at 15.3%; +1% → 16.3%, still below prior 18% target. Dependent on capacity utilization (Silvassa to 85-90%, Taloja to 75% by Q4), fixed cost absorption.
PAT margin 9-10% by end FY27 (vs. Q1 actual 6.0%)
LowRequires +3-4 pp improvement in 3 quarters. Q2 not expected to improve (early in ramp). Q3-Q4 must deliver. Credibility test in Q2 earnings.
UAE capex AED15 Mn (third tempering line, fire-rated technology; installation by Q3 commercial production)
HighFunded via internal accruals + AED7 Mn bank debt. Adds 24 lakh sq meter capacity. Increases total UAE capacity by ~24%. Already in installation phase.
India capex <₹1 Cr annual (maintenance, critical realignment, machine overhauling)
HighNo major brownfield/greenfield expansion planned; acquired capacity (Taloja, Erode) still ramping. Future expansion dependent on market opportunity.
Risks the call surfaced
Margin recovery execution
HighQ1 PAT 6% vs. FY27 guidance 9-10%. Management attributes to one-offs (appraisals, labor agreement, logistics). If Q2 doesn't show margin inflection, credibility erodes and full-year guidance at risk.
Geographic concentration (UAE)
HighUAE accounts for 69% of Q1 revenue (₹81.5 Cr). Geopolitical tensions mentioned (June war, logistics disruption). Any escalation in Middle East tensions could impact operations, pricing, execution.
Capacity scaling execution
MediumCompany targeting utilization improvements across 3 India plants (Silvassa 77%→90%, Taloja 55%→75%, Erode 15%→30%) and UAE (71%→85%) by Q4. Taloja and Erode are recent acquisitions still ramping. Failure to ramp utilization will miss margin improvement targets.
Customer concentration
MediumIndia business: top 15 clients contribute ~70% of revenue. Heavy reliance on Godrej, L&T, Prestige, Raheja. Loss of major customer or project delay could impact revenue and margins.
Tailor-made product execution risk
LowUAE customer delay in releasing sizes (due to architect approvals, site readiness) creates working capital cycle risk and mismatch between order book and monthly execution. July showed AED11.87 Mn (near ceiling), but monthly can be lumpy.
Management
Score 7/10. Clear and candid on operational metrics (utilization, order book, capex). Transparent on margin pressure drivers (appraisals, labor agreement, logistics, input costs). Some hedging on long-term guidance (25-40% range is wide). Addressed analyst pushback directly without evasion. Track record mixed. Prior FY26 guidance ₹400 Cr+ likely met (~₹470 Cr annualized Q1 run-rate), but margin target 16-16.5% EBITDA appears to have slipped to 15-16%. Q1 shows strong revenue but compressed PAT, testing credibility of margin recovery narrative.
1 · Q2 FY27
Margin improvement from higher capacity utilization (targeting 140-145 Cr revenue, ~18-23% QoQ growth)
2 · Q3 FY27
UAE third tempering line goes live (24 lakh sq meter annual capacity); fire-rated technology commercialization
3 · Q3-Q4 FY27
Fixed-cost absorption from seasonal ramp (Navratri, Diwali, Christmas; post-monsoon construction surge)
Key risk: UAE concentration (69% of Q1 revenue) amid geopolitical uncertainty.
Revenue Up 53%, But Margins Hit a Five-Quarter Low — Margin Recovery Unproven
Sejal delivered a blowout 52.9% revenue growth, yet Q1 PAT margins compressed to 6%—the weakest in five-six quarters. Management pins recovery on capacity utilization ramping from Q3. That bet is not yet supported by Q2 guidance.
₹117.9 Cr
+52.9% YoY, +3.0% QoQ
₹7.2 Cr
+63.4% YoY, −36.8% QoQ
15.3%
vs. 18% prior target
₹225 Cr
6–9 month execution window
The Core Tension
Sejal Glass delivered headline growth that ought to impress—revenue up 53% year-on-year, across both India and UAE operations. PAT rose 63% in absolute terms. Yet the quarter was marred by the worst margin compression in five-six quarters. Q1 PAT margin landed at 6.0%, down sharply from Q4 FY26's implied 11%+, and significantly below management's full-year guidance of 9–10% PAT margin. This gap—between the eye-catching growth and the margin deterioration—is what the quarter really was about.
Where the Margin Pressure Came From
Management attributed Q1's margin compression to four drivers, each cited as temporary: (1) performance appraisals and annual increments (~₹1 Cr impact); (2) Taloja plant labor union agreement (incremental people cost ~₹1 Cr); (3) UAE logistics disruption in June (no quantum disclosed); and (4) input cost inflation of 1% (diesel, energy surcharge). Collectively, management framed these as one-time headwinds that will clear by Q2, with margin recovery accelerating in Q3–Q4 via capacity utilization gains. That narrative is plausible but unproven—and critically, management offered no Q2 margin guidance, only a generic assertion that 'Q3 and Q4 will see margin impact recovery.'
EBITDA increased 44% YoY to ₹18 Cr
₹18 Cr = 15.3% margin; prior target was 18% EBITDA margin
Overstated—margin compression vs. target
PAT growing 63% YoY to ₹7.22 Cr
₹7.22 Cr confirmed; but −36.8% QoQ signals deterioration within year
Supported (number correct, but trend is concerning)
9–10% PAT margin guidance for FY27
Q1 at 6.0%; requires +3–4 pp improvement in 9 months
Overstated—requires unproven utilization ramp
EBITDA margin improvement ~1% over upcoming quarters
15.3% + 1% = 16.3%, still well short of prior 18% aspiration
Overstated—insufficient to meet prior guidance
Strong order inflow ₹50 Cr India, AED72 Mn UAE
Confirmed at these levels; 6–9 month execution window provides visibility
Supported
What Changed on This Call
Margin target implicitly downgraded. Prior guidance cited ₹400 Cr+ revenue with 16–16.5% EBITDA margin for FY26–27. The 18% EBITDA aspiration has been quietly shelved; management now speaks of '~1% improvement over upcoming quarters,' moving the bar from 18% to 15–16%. This is a material step down, even if it went unannounced.
Revenue guidance widened. Prior minimum guidance was 25% growth for FY27. Now management cites 25% minimum with 40% potential upside. Q1's 52.9% beat validates the upside case, making the 25% minimum look conservative—but also raising questions about the credibility of a guidance range that went this wide.
Capacity expansion accelerated. UAE third tempering line (AED15 Mn capex) will add 24 lakh sq meter annual capacity and go live by Q3. India plants (Taloja, Erode, recently acquired) are ramping utilization targets from 55% and 15% to 75% and 25–30% respectively by Q4. This is an upgrade in capex ambition.
Geographic rebalancing timeline accelerated. Management now targets 60–40 UAE-to-India mix this year (vs. historical 75–25), and 50–50 by next year. This addresses concentration risk—69% of Q1 revenue came from UAE—but execution depends on India scaling faster.
The Bull-Bear Ledger
Revenue growth 52.9% YoY is material and broad-based (India +67%, UAE +47%)
Order book ₹225 Cr provides 6–9 month revenue visibility and supports Q2–Q3 momentum
Capacity expansion (UAE third line, Taloja/Erode ramp) supports 25–40% long-term growth targets
Q1 PAT margin 6% is the lowest in 5–6 quarters—a material deterioration
Margin recovery dependent entirely on utilization ramp by Q3–Q4; Q2 expected soft with no uplift
UAE concentration at 69% of Q1 revenue; geopolitical risk (June logistics disruption mentioned)
Top 15 clients account for ~70% of India revenue; customer concentration risk
Guidance consistency weakened (25% vs. 50% growth reference required clarification)
Earnings Quality & Credibility Test
Analysts (Raj Saraf, Nishitha, Shanki Bansal) pressed hard on the margin deterioration. Q1 at 6% PAT vs. 9–10% guidance triggered skepticism on sustainability. Management held firm—cited appraisals, labor agreement, logistics, input costs as one-offs—but offered zero Q2 margin guidance to validate the recovery path. This silence is itself a red flag. If Q2 PAT margin remains below 7.5%, the full-year 9–10% guidance will be credibly at risk.
The other credibility risk: prior FY26 guidance spoke of 16–16.5% EBITDA margin. Q1 at 15.3% already underperforms. Management now claims +1% improvement ahead, which would reach 16.3%—still a miss on the original 16–16.5% band. The implicit downgrade from 18% to 15–16% was not flagged as a guidance cut, which undermines transparency.
How the Street is Positioned
The stock sits at ₹720 as of early August, down 30.6% from its all-time high and trading below all three key moving averages (SMA20 ₹737, SMA50 ₹767, SMA200 ₹746). RSI at 43.5 signals neutral momentum, and volume has been declining—a sign of waning interest. The stock has recovered 86% from its 52-week low of ₹387, but the rally has stalled and the market appears skeptical of further upside.
Institutional positioning reflects caution. FII ownership remains minimal at 0.19% (flat quarter-on-quarter), and DII at 4.54% shows no aggressive accumulation. Promoter ownership is steady at 69.96%, but there is no evidence of insider buying on the dip. This institutional apathy, combined with the stock's downtrend and below-average volume, suggests the street is unconvinced by the margin recovery narrative. The drawdown is not being treated as a bargain; it is being treated as a warning.
The post-result price action (though not explicitly provided) would normally clarify whether the street bought the margin guidance or rejected it. Given the stock's sustained decline and below-average volume, it is reasonable to infer that the market did not take comfort in management's one-off excuses. The burden is now on Q2 results to prove the recovery is real.
Ranked Risks (by Holder Concern)
Margin recovery pathway unproven; Q2 credibility test
HighPAT margin 6% vs. 9–10% guided = 3–4 pp gap. If Q2 doesn't show uptick (7.5%+), full-year guidance credibility erodes and stock will re-rate lower.
UAE concentration (69% of Q1 revenue) amid geopolitical volatility
HighJune logistics disruption mentioned but not quantified. Any escalation in Middle East tensions could disrupt execution, pricing, and delivery timelines. Geographic rebalancing to 50–50 by FY28 is aspirational, not current state.
Capacity scaling execution (Taloja 55%→75%, Erode 15%→30% by Q4)
MediumThese are recent acquisitions still ramping. Failure to hit utilization targets will directly miss the margin recovery driver. Q2–Q3 will clarify track record.
Customer concentration (top 15 clients = 70% of India revenue)
MediumLoss of a major customer (Godrej, L&T, Prestige, Raheja) or project delay would impact revenue and margin assumptions. Pricing power limited by developer-driven architecture market.
Tailor-made product execution delays in UAE (order book AED72 Mn vs. monthly AED11.87 Mn July sales)
LowCustomers release product sizes based on site readiness and architect approvals, creating lumpy execution. Working capital cycle risk if delays persist. But 95%+ on-time delivery track record suggests management capability.
What to Watch Next (Q2–Q3)
1 · Q2 PAT margin trajectory (the credibility test)
Target: PAT margin ≥7.5% to validate recovery narrative. Anything <7% will signal full-year 9–10% guidance is at risk. This is the single most important number from here.
2 · Capacity utilization ramp (Silvassa 77%→85–90%, Taloja 55%→75%, Erode 15%→25–30% by Q4)
These are the stated drivers of margin recovery. Q2–Q3 results must show sequential progress. Flat or declining utilization will undermine the fixed-cost absorption thesis.
3 · UAE third tempering line commercial launch (target Q3)
24 lakh sq meter capacity addition, fire-rated tech commercialization. If delayed or underutilized at launch, the long-term growth story (25–40% CAGR) loses credibility. Track capex spend and timeline against AED15 Mn target.
The Verdict
Sejal Glass delivered headline growth but margin compression in Q1 that the market has not forgiven. The stock is down 30% from its high, below all key moving averages, and institutional investors are sitting on the sidelines. Management's one-off excuses for the margin miss are plausible but unproven; the company has offered zero Q2 guidance to validate the recovery. This is not a step-change result—it's a steady execution test, and management has failed the opening credibility test.
The number to track from here is Q2 PAT margin. Anything above 7.5% validates the utilization-ramp thesis and keeps the 9–10% full-year guidance alive. Anything below 6.5% signals the margin headwinds are structural, not temporary, and the stock will re-rate materially lower. Current positioning: Hold, pending Q2. Add only after Q2 confirms margin inflection; until then, the burden of proof remains with management.